Kambô for Health & Longevity

Created on 11/01/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Kambô, an Amazonian frog's skin secretion applied to small burns, is promoted as a cleanse, mood aid and immune tonic. It triggers a violent but usually brief purge. Evidence for benefit is thin: surveys of volunteer users report better well-being and less alcohol and drug use. Case reports describe serious harms of unknown frequency, including dangerous drops in blood sodium, seizures, sudden heart-related death and tearing of the esophagus. (Full Review)

Protocol

Standard Western session
1–20 small burn points
Mean 6.3 points; secretion per point not standardized
Series pattern
About three sessions within a month
Followed by occasional sessions, as practitioners commonly describe
Regulatory position
No medical dosing protocol exists
Australia prohibits supply and use; not an approved medicine in New Zealand
Time to effect
Longer-term effects
Lasting 8–30 days or 1–6 months
Predominantly positive; each duration reported by about a quarter of survey respondents; no control group
Conviction of benefit
Within days
Rose in the days after a first session; retrospectively rated by users
Acute effects
Within minutes
Usually last 15–60 minutes; drowsiness and apathy follow the acute phase

Benefits

Contraindications
  • Pregnancy
  • Heart disease (coronary disease, LVH, arrhythmia, unexplained fainting)
  • Serum sodium below 135 mmol/L or use of sodium-lowering drugs
  • Seizure disorders
  • Psychotic or bipolar disorders
  • Active cancer
  • Liver or kidney disease
  • Esophageal disease or recent chest or abdominal surgery
  • History of angioedema or hereditary angioedema
  • Children and people of low body weight
Key Interactions
  • Large-volume water intake
Theoretical (inferred from mechanism)
  • Opioid blockers (naloxone)
  • Thiazide diuretics (hydrochlorothiazide), SSRIs (sertraline) and carbamazepine
  • ACE inhibitors (lisinopril) and sacubitril/valsartan
  • Blood-pressure-lowering drugs (amlodipine), PDE5 inhibitors (sildenafil) and nitrates (nitroglycerin)
  • Opioids (oxycodone), benzodiazepines (alprazolam), gabapentinoids (gabapentin) and alcohol
  • Digoxin and QT-prolonging drugs (sotalol)
  • Over-the-counter NSAIDs (ibuprofen)
  • Over-the-counter decongestants (pseudoephedrine)
  • Kratom (Mitragyna speciosa) supplements
  • Blood-pressure-lowering supplements (beetroot nitrate)
  • Licorice (glycyrrhizin) and stimulant laxatives (senna)
  • Ayahuasca, 5-MeO-DMT and rapé in combined ceremonies
  • Fasting, colon cleanses and saunas
  • Cancer chemotherapy and immunotherapy (cisplatin, pembrolizumab)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Acute purging reaction; severe hyponatremia and seizures; sudden cardiac death; esophageal rupture; toxic hepatitis; psychosis and lasting neuropsychiatric change; systemic inflammation, muscle breakdown and kidney injury; immune-mediated muscle, nerve and blood-vessel disorders; delayed effective treatment; burn-site scarring
  • Speculative: Pregnancy loss; mislabeled or adulterated secretions

Monitoring

Marker Target Why
Serum sodium 135–145 mmol/L Safety check: a low value stops use
Serum potassium 3.5–5.0 mmol/L Safety check: a low value stops use
Resting ECG (rhythm and QTc) Sinus rhythm; QTc below 450 ms in men and 460 ms in women Safety check: an abnormal rhythm or prolonged QTc stops use
ALT Up to about 40 U/L Safety check: a rise stops use
Serum creatinine About 0.6–1.2 mg/dL Safety check: a rise stops use
Creatine kinase About 30–200 U/L Safety check: a marked rise signals muscle breakdown and stops use
hCG Negative Safety check: a positive result stops use
Plasma and urine osmolality Not specified in the ER Paired with sodium to identify water retention by the kidneys
Magnesium Not specified in the ER Paired with potassium
AST Not specified in the ER Paired with ALT; liver and muscle enzyme
eGFR Not specified in the ER Paired with creatinine; kidney filtration

Cadence: Baseline panel before a first session; sodium within 2–6 hours after any session with persistent vomiting, headache, confusion or weakness; repeat panel at 24–48 hours if symptoms continue; hCG before each session; ECG repeated if palpitations or fainting occur after a session; creatine kinase after seizures or prolonged weakness; full baseline panel before each new session series, or every 3–6 months for repeated users.

Qualitative Assessment

  • Well-being and mood: self-rated life satisfaction, mood and anxiety before and in the weeks after a session
  • Substance use: frequency of alcohol, tobacco and recreational drug use compared with baseline
  • Energy and sleep: daytime energy, fatigue and sleep quality over the following week
  • Persistent symptoms: any weakness, numbness, confusion, behavioral change, chest pain or swelling lasting beyond the session day
  • Burn-site healing: redness, discharge or scarring at application points